CTRI/2010/091/000162招募中2 期
A Phase 2, Randomized, Double-Blind, Placebo and Active-Comparator Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 weeks as monotherapy in Patients with Type 2 Diabetes Mellitus.
Metabolex Inc0 个研究点目标入组 100 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •a) History of type 2 diabetes of at least 3 months duration
- •b) Treatment-naïve (not on any anti-diabetic medication) or treated with a single anti-diabetic agent (excluding insulin, exenatide or other GLP-1 analogs, pioglitazone or rosiglitazone)
- •c) HbA1c 7.0-8.5% (inclusive) at screening
- •d) Fasting glucose should be more than or equal to 105 mg/dL and less than or equal to 250 mg/dL at screening and randomization visit
- •e) Adult male or female, 18-70 years of age
排除标准
- •a) History of outpatient insulin use within last one year
- •b) Weight loss > 10 pounds in the 3 months prior to screening visit or use of weight loss medications (prescription or OTC) within 30 days of screening
- •c) History of GLP-1 analogue or DPP-4 inhibitor discontinuation due to side effect or lack of efficacy.
研究者
相似试验
已完成
不适用
A Phase 2, Double-Blind, Randomized, Placebo and Active-Controlled Dose-Finding Study to Assess the Efficacy, Safety and Tolerability of Multiple Oral Doses of ASP1941 in Patients With Type 2 Diabetes MellitusPER-013-10Astellas Pharma Global Development, Inc. (APGD),
已完成
2 期
A study to evaluate the effect of ASP 1941 in adult patients with type 2 diabetes mellitusCTRI/2010/091/000343Astellas Pharma Inc378
已完成
2 期
A Phase 2a Randomized, Double-Blind, Placebo and Active Comparator-Controlled, Parallel Group, Dose-Range Finding Study of MVT-602 in Healthy Premenopausal Women Undergoing Controlled Ovarian Stimulation (COS) Using a Minimal Stimulation Protocol.NL-OMON46304Myovant Sciences GmbH85
进行中（未招募）
1 期
A study to investigate the sex-hormone-stimulant study drug MVT-602 in healthy fertile women.EUCTR2018-001379-20-NLMyovant Sciences GmbH85
进行中（未招募）
不适用
A phase II, randomized, double-blind, placebo and active controlled, parallel group, multi-center, dose ranging study to evaluate the efficacy and safety of LCI699 compared to placebo after 8 weeks treatment in patients with resistant hypertension.MedDRA version: 9.1Level: LLTClassification code 10020772Term: Hypertensionresistant hypertensionEUCTR2008-007338-23-ISovartis Pharma Services AG250